We hypothesized that combined therapy with AMD3100 and a standard chemotherapeutic drug would significantly improve tumor control and survival, based on studies in leukemia showing that CXCL12 in the tumor microenvironment confers resistance to standard cytotoxic drugs [33]. The gene discussed is CXCL12; the disease is leukemia.